Which medications in the drug class Beta-Blockers, Nonselective are used in the treatment of Chronic Glomerulonephritis?

1. Kawasaki Y. Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment. Pediatr Int. 2011 Dec. 53(6):795-806. [Medline].

2. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2011 Dec 7. [Medline].

3. Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009 Oct. 24(10):3068-74. [Medline]. [Full Text].

4. Schöll U, Wastl U, Risler T, Braun N, Grabensee B, Heering P, et al. The "point of no return" and the rate of progression in the natural history of IgA nephritis. Clin Nephrol. 1999 Nov. 52(5):285-92. [Medline].

5. Fernandes das Neves M, Irlapati RV, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford). 2015 Aug. 54 (8):1403-7. [Medline].

6. Wang Y, Huang X, Cai J, Xie L, Wang W, Tang S, et al. Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody: A Retrospective Study. Medicine (Baltimore). 2016 Jan. 95 (4):e2580. [Medline].

7. Nakai S, Wada A, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial. 2006. 10:476-97. [Medline]. [Full Text].

8. Research Group on Progressive Chronic Renal Disease. Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Nephron. 1999. 82(3):205-13. [Medline].

9. Blowey DL, Warady BA. Outcome of infants born to women with chronic kidney disease. Adv Chronic Kidney Dis. 2007. 14:199-205. [Medline].

10. Imbasciati E, Gregorini G, Cabiddu G, Gammaro L, Ambroso G, Del Giudice A, et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis. 2007. 49:753-62. [Medline].

11. Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S. Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis. Nephrol Dial Transplant. 2010 Dec. 25(12):3948-56. [Medline].

12. Hindricks J, Ebert T, Bachmann A, Kralisch S, Lössner U, Kratzsch J, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf). 2014 Jun. 80 (6):918-24. [Medline].

13. Abou-Mrad RM, Abu-Alfa AK, Ziyadeh FN. Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. Am J Physiol Renal Physiol. 2013 Sep 1. 305(5):F613-7. [Medline].

14. Wolf G. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis. Nat Clin Pract Nephrol. 2008 Sep. 4(9):474-5. [Medline].

15. Tsuruoka S, Kai H, Usui J, Morito N, Saito C, Yoh K, et al. Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis. Intern Med. 2013. 52(3):303-8. [Medline].

16. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005. 67:799-812. [Medline].

17. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10. 358(15):1547-59. [Medline].

18. Omae K, Ogawa T, Nitta K. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels. 2009 Jul. 24(4):301-7. [Medline].

19. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007 Sep. 2(5):906-13. [Medline].

20. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 Sep. 20(9):2075-84. [Medline]. [Full Text].

21. Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010 Aug. 78(3):303-9. [Medline].

22. Goraya N, Simoni J, Jo CH, Wesson DE. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol. 2013 Mar. 8(3):371-81. [Medline]. [Full Text].

23. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 Jun 5. 358(23):2433-46. [Medline].

24. Naguib MT. Kidney disease in the obese patient. South Med J. 2014 Aug. 107(8):481-5. [Medline].

25. Cameron JS. The Long-Term Outcome of Glomerular Diseases. Schrier RW, Gottschalk CW, ed. Diseases of the Kidney. 6th ed. Little, Brown & Company: Boston, Mass; 1997. 1919.

26. [Guideline] K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb. 39(2 Suppl 1):S1-266. [Medline].

27. Murray SL, Dorman A, Benson KA, Connaughton DM, Stapleton CP, Fennelly NK, et al. Utility of Genomic Testing after Renal Biopsy. Am J Nephrol. 2020. 51 (1):43-53. [Medline].

28. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004 Dec 21. 141 (12):929-37. [Medline].

Moro O Salifu, MD, MPH, FACP Associate Professor, Department of Internal Medicine, Chief, Division of Nephrology, Director of Nephrology Fellowship Program and Transplant Nephrology, State University of New York Downstate Medical Center

Moro O Salifu, MD, MPH, FACP is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Society of Transplantation, American Society of Diagnostic and Interventional Nephrology, American Medical Association, American Society for Artificial Internal Organs, American Society of Nephrology, National Kidney Foundation

Disclosure: Nothing to disclose.

Barbara G Delano, MD, MPH, FACP Professor and Chair, Department of Community Health Sciences, School of Public Health, State University of New York Downstate

Barbara G Delano, MD, MPH, FACP is a member of the following medical societies: American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Vecihi Batuman, MD, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Interim Chair, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

George R Aronoff, MD Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment